arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

NextCure, Inc.

NXTC
$5.88 ▲ +0.36 (+6.52%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
34 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
14
Health
Poor
Bearish
auto_awesome

Analytical Summary

NextCure, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $30.8M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -29.9%
FCF / Share $-2.55
Trailing P/E
Price / Book 0.8x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

34-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-9.80M
↑ +10.8%
FCF / Share Free cash flow per share
$-2.55
↑ +56.0%
Long-Term Debt Long-term obligations
$972.00K
↓ -30.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
4
Financial Health
5
Cash Quality
60

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 9 years · 34 quarters